MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) was featured in a recent TechMediaWire Podcast, where CEO Justin Hanka discussed the company’s plans to commercialize AI-powered voice analysis technology designed to detect alcohol and drug intoxication through non-invasive speech assessment. During the interview, Hanka explained that the company has built prediction models using more than 50 million data points collected through years of clinical research, enabling the identification of intoxication indicators associated with alcohol and drug use.
MindBio believes its technology offers a scalable alternative to traditional testing methods that require biological samples, with potential applications in mining, aviation, construction, law enforcement and other safety-sensitive industries. The company is developing enterprise deployment systems that combine proprietary software with Edge-AI kiosks capable of delivering assessments in less than three seconds and expects to begin live workplace testing during the second quarter of 2026. Looking beyond workplace impairment detection, management also sees broader opportunities for AI-driven voice analytics as a diagnostic tool for identifying physiological and neurological conditions.
To view the full article, visit https://ibn.fm/HJarm.
MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF.
